Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer
NCT01587820
Terminated
This is a randomized, open-label investigator initiated pilot/ feasibility study comparing the effectiveness of intra-arterial administration of cisplatin therapy to intravenous administration of cisplatin when each is combined with the radiation therapy found in standard care. Participants will be randomized to either intra-arterial or intravenous cisplatin chemotherapy. This study is designed to determine whether a large scale study is practical in the investigators clinical setting. Approxima... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2014
Locations: Southern Illinois University School of Medicine, Springfield, Illinois +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
NCT00253370
Completed
This phase II trial is studying how well giving sorafenib together with docetaxel and cisplatin works in treating patients with metastatic or locally advanced gastric or gastroesophageal junction cancer that cannot be removed by surgery. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
Register for Updates
Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
NCT00002932
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and radiation therapy in treating patients with stage IV cancer of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: University of California San Diego Cancer Center, La Jolla, California +12 locations
Conditions: Head and Neck Cancer
Register for Updates
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
NCT00388154
Completed
Primary Objective: * To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: * To determine the nature and degree of toxicity of the combination of gemcitabine and cisplatin in this cohort of patients.
Gender:
FEMALE
Ages:
All
Trial Updated:
11/12/2014
Locations: St. Lukes Episcopal Hospital, Houston, Texas +2 locations
Conditions: Endometrial Cancer
Register for Updates
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
NCT00165490
Completed
The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2014
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Register for Updates
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
NCT00799240
Completed
This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how long we can control the cancer growth and toxicity and safety of the combination. Laboratory research with the tumor tissue and blood obtained will be done to assess IGF-1R expression and related markers and correlate with response and survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2014
Locations: Hutchinson Clinic, PA, Hutchinson, Kansas +3 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00726986
Terminated
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2014
Locations: Columbia Presbyterian, New York, New York +10 locations
Conditions: Lung Cancer
Register for Updates
Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
NCT00808145
Withdrawn
This study will look at the safety and efficacy of treating advanced hepatocellular carcinoma in patients who have not yet received systemic chemotherapy. Previous local treatment of hepatic lesions is permitted The treatment will use a combination of three FDA approved chemotherapy drugs, Gemcitabine, Cisplatin and Sorafenib. Sorafenib is FDA approved for the treatment of hepatocellular cancer, gemcitabine and cisplatin are not approved for the treatment of hepatocellular cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/21/2014
Locations: Lahey Clinic, Burlington, Massachusetts
Conditions: Hepatocellular Carcinoma
Register for Updates
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
NCT00006389
Completed
Phase II trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients who have metastatic or unresectable stomach cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin 1 may increase the effectiveness of cisplatin by making tumor cells more sensitive to the drug. Combining cisplatin with bryostatin 1 may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2014
Locations: University of Southern California, Los Angeles, California
Conditions: Stage III Gastric Cancer, Stage IV Gastric Cancer
Register for Updates
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
NCT01790516
Terminated
This study is for patients with newly diagnosed head and neck cancer that cannot be removed by surgery. The purpose of this study is to determine the feasibility of using genetic variations in patients to select the right drug to treat head and neck cancer. Cisplatin and cetuximab (Erbitux)are both approved by the FDA to treat head and neck cancer in combination with radiation therapy. In this study the investigators will test whether genetic differences between patients can be used to pick whi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2014
Locations: Georgetown Lombardi Comprhensive Cancer Center, Washington, District of Columbia
Conditions: Head and Neck Squamous Cell Cancer
Register for Updates
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
NCT00109928
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV T-cell non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2014
Locations: Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona +76 locations
Conditions: Lymphoma
Register for Updates
Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus
NCT00208936
Terminated
This study is designed pre-operative for patients with resectable, local-regional carcinoma of the esophagus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2014
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Esophageal Diseases
Register for Updates